荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

午间休市 01-13 12:05:00

103.600

+10.800

+11.64%

最高106.600	最低99.550	成交量1,395万
今开101.000	昨收92.800	日振幅7.60%
总市值583.90亿	流通市值216.09亿	总股本5.64亿
成交额14.30亿	换手率6.69%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":103.6,"timestamp":1768277100006,"preClose":92.8,"halted":0,"volume":13949329,"delay":0,"floatShares":208581239,"shares":563608243,"eps":-3.0539066045902246,"marketStatus":"午间休市","change":10.8,"latestTime":"01-13 12:05:00","open":101,"high":106.6,"low":99.55,"amount":1429791675,"amplitude":0.07597,"askPrice":103.7,"askSize":1500,"bidPrice":103.6,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.9522685259574661,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768280400000},"marketStatusCode":3,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":92.8,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":6.561956,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":114.46,"timestamp":1768275000000,"preClose":95.38,"halted":0,"volume":15673000,"delay":0,"premium":"-19.09"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2603575987","title":"商业航天大面积跌停，AI应用继续大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575987","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575987?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:06","pubTimestamp":1768270010,"startTime":"0","endTime":"0","summary":"大河财立方记者 夏晨翔 任浩鹏1月13日开盘，A股三大指数集体高开后震荡，医疗、CRO、生物科技、AI应用、文化传媒、虚拟人、AIGC、保险等概念涨幅居前；商业航天、卫星导航、低空经济、卫星互联网等概念跌幅居前。12日晚间，多个热门赛道概念股发布异常波动、风险提示、停牌核查公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","300063","LU1328277881.USD","LU2153592121.USD","LU2399975544.HKD","002131","LU0348827113.USD","300785","HYDD.SI","LU1770034418.SGD","603986","LU0449515922.USD","LU2097828631.EUR","LU0823426308.USD","LU0164865239.USD","LU0828238088.HKD","LU0359201885.HKD","300244","LU0509642566.USD","LU0871576103.HKD","LU0594300419.USD","600151","LU0505663152.USD","LU0865486749.SGD","LU1242518931.SGD","LU2778985437.USD","LU0819123356.HKD","LU0143863198.USD","LU0417516902.SGD","LU0823426480.USD","LU1880383440.USD","LU0314109678.HKD","600986","09988","BYDDY","01211","LU0164872284.USD","LU0327786744.USD","LU0572944931.SGD","LU1861214812.USD","LU2357125470.USD","LU0289960550.SGD","BK1610","LU0143863784.USD","LU0634319403.HKD","688331","LU0054450605.USD","LU0588545490.SGD","LU0588545730.USD","LU1720050803.USD","LU0516423091.SGD","LU1794554557.SGD","SG9999001226.SGD","LU0259732245.USD","LU2476274308.USD","LU0650527681.SGD","LU1868838027.USD","IE00BD6J9T35.USD","301171","LU1303224171.USD","LU2249611893.SGD","BK1539","LU1961090484.USD","LU0856984785.SGD","LU0823039010.USD","LU0348735423.USD","LU0516422366.SGD","002044","LU1242518857.USD","LU0289961442.SGD","LU0823038988.USD","09995","LU1188198961.HKD","LU0531971595.HKD","LU0593848301.USD","LU0084288322.USD","LU2476274720.SGD","LU2506951792.HKD","LU0540923850.HKD","LU0269904917.USD","LU0543330566.HKD","LU1861219969.SGD","LU2360107325.USD","LU0516422440.USD","LU0516422952.EUR","LU0819121731.USD","SG9999014674.SGD","LU0229945570.USD","SG9999015986.USD","LU0214875030.USD","81211","LU0244354667.USD","002149","SG9999006514.SGD","LU0289739343.SGD","LU1813983027.USD","LU1868837722.USD","LU0039217434.USD","LU0588545904.SGD","600880","LU2097828805.USD","09868","LU0254981946.USD","SG9999002828.SGD","LU2039709279.SGD","LU0594300179.USD","BK1509","LU0561508036.HKD","LU0043850808.USD","LU2097828557.USD","LU0052750758.USD","LU0516423174.USD","LU0823414478.USD","BK1119","LU0359202008.SGD","LU0979878070.USD","000547","LU1880383366.USD","BK1522","LU0469268626.HKD","LU0165289439.USD","LU0449509016.USD","603598","LU2348774022.SGD","SG9999002463.SGD","LU0531970944.HKD","LU0315178854.USD","LU2294711713.HKD","BK1582","002413","LU0605514214.HKD","LU0823414551.USD","LU2097828714.EUR","LU1023057109.AUD","601698","LU0359201612.USD","LU1808992512.USD","LU1868837565.USD","603259","LU2449936058.SGD","SG9999015978.USD","LU2097828474.EUR","SG9999006597.SGD","SG9999015945.SGD","LU0348805143.USD","LU0348825331.USD","LU0417516738.SGD","LU0211977185.USD","BK1540","LU0708995583.HKD","LU0175139822.USD","02359","BK1594","LU0326950275.SGD","LU0511384066.AUD","LU0307460666.USD","03986","LU1251922891.USD","301230","LU0320764599.SGD","LU1719994722.HKD","LU0463099449.HKD","002594","SG9999015952.SGD"],"gpt_icon":1},{"id":"2603357301","title":"PD-1/VEGF双抗交易热潮回归？荣昌生物签下56亿美元授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603357301","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603357301?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:03","pubTimestamp":1768269780,"startTime":"0","endTime":"0","summary":"艾伯维拿下荣昌生物的双抗授权。　　1月12日晚间，中国生物医药企业荣昌生物宣布，与艾伯维达成一笔总金额高达56亿美元的授权合作。　　RC148是荣昌生物研发的一款新型靶向PD-1/VEGF的双特异性抗体药物，其设计旨在激活抗肿瘤免疫反应的同时抑制肿瘤驱动的血管生成。通过同时靶向并抑制PD-1与VEGF通路，有望通过多机制增强免疫系统的抗肿瘤活性。　　值得一提的是，康方生物PD-1/VEGF再度传来新的进展消息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU1064130708.USD","LU1064131003.USD","LU1169590202.USD","LU1969619763.USD","BK1583","688331","BK4023","LU1169589451.USD","09995","LU2148510915.USD","BK1574","BK1161","LU2488822045.USD","LU2328871848.SGD","PD"],"gpt_icon":0},{"id":"1161784801","title":"异动解读 | 荣昌生物盘中大涨8.84%，与艾伯维达成56亿美元重磅授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1161784801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161784801?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:30","pubTimestamp":1768267834,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中大涨8.84%，引发市场广泛关注。消息面上，荣昌生物于1月12日宣布与跨国药企艾伯维签署独家授权许可协议，将其自主研发的PD-1/VEGF双特异性抗体药物RC148在大中华区以外的开发、生产和商业化权利授予艾伯维。根据协议，荣昌生物将获得6.5亿美元的首付款，并有资格获得最高达49.5亿美元的里程碑付款及销售分成，总交易金额最高可达56亿美元。此次与艾伯维的合作不仅为荣昌生物带来急需的资金支持，也彰显了其创新药物的全球竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0},{"id":"1191847999","title":"荣昌生物与艾伯维签署授权许可协议，最高可获49.5亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1191847999","media":"老虎资讯综合","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191847999?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:29","pubTimestamp":1768267782,"startTime":"0","endTime":"0","summary":"1月13日，荣昌生物大涨逾10%！与艾伯维签署授权许可协议，最高可获49.5亿美元里程碑付款。荣昌生物公告称，公司与艾伯维就RC148签署独家授权许可协议，艾伯维将获得RC148在大中华区以外地区的开发、生产和商业化的独家权利。协议生效后，荣昌生物将收到6.5亿美元首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地区净销售额的两位数分级特许权使用费。本次许可交易有助于加速RC148的全球开发和商业化进程，并提升公司的品牌价值和国际影响力。但需注意，由于创新药品的不确定性，最终付款金额尚存在不确定性。","market":"us","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荣昌生物与艾伯维签署授权许可协议，最高可获49.5亿美元里程碑付款","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"gpt_icon":0},{"id":"2603229535","title":"智通港股早知道 | 四部门印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》 隔夜中概股指数涨4.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603229535","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603229535?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:43","pubTimestamp":1768261383,"startTime":"0","endTime":"0","summary":"四部门联合印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》国家发展改革委等四部门联合印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》。热门中概股多数收涨，纳斯达克中国金龙指数涨4.26%，阿里巴巴涨超10%，创8月29日以来最大涨幅；哔哩哔哩涨近9%，小鹏汽车涨超8%。减持后最新持股数目约为47.19亿股，最新持股比例为70.20%。指纹识别模组销售数量合计1794.7万件，环比增加0.9%，同比减少12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1560","BK1610","LU0572940350.SGD","LU1497734951.SGD","BK1614","LU1634259557.SGD","LU1497733557.USD","09995","BK1117","LU0264606111.USD","BK1231","BK1119","LU1522347837.USD","LU1634259391.SGD","BK1161","LU0210526637.USD","LU0051755006.USD","LU0456827905.SGD","BK1526","LU1497733631.SGD","LU0572939691.SGD","688331","BK1163","BK1607"],"gpt_icon":1},{"id":"2603530529","title":"艾伯维与荣昌生物达成合作 共同开发实体瘤实验性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2603530529","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603530529?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:04","pubTimestamp":1768226651,"startTime":"0","endTime":"0","summary":"来源：环球市场播报艾伯维公司于周一宣布，将与荣昌生物达成合作，共同开发一款实体瘤实验性疗法。该合作协议总价值最高可达49.5 亿美元，其中包含里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112220644a4bafb3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112220644a4bafb3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU2328871848.SGD","LU1969619763.USD","09995","BK1161","BK1574"],"gpt_icon":0},{"id":"2602517177","title":"荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517177","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517177?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:54","pubTimestamp":1768222464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年1月12日，公司与艾伯维集团控股公司(艾伯维)就RC148签署独家授权许可协议。RC148是公司研发的一款新型靶向PD-1/VEGF的双特异性抗体药物。根据协议，艾伯维将获得RC148在大中华区以外地区的的开发、生产和商业化的独家权利。协议经相关监管批准生效后，公司将收到6.5亿美元的首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地区净销售额的两位数分级特许权使用费。协议中所约定的里程碑付款需要满足一定的条件，公司最终可实现的里程碑付款金额尚存在不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","09995","BK1574","LU2148510915.USD","688331","BK0239","BK1583","LU1064130708.USD","LU1064131003.USD","BK1161","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2602933518","title":"JPM 2026前瞻 | 中国创新药站上全球舞台中央","url":"https://stock-news.laohu8.com/highlight/detail?id=2602933518","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602933518?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:58","pubTimestamp":1768208280,"startTime":"0","endTime":"0","summary":"2026年第44届摩根大通医疗健康大会将于1月12日至15日在美国旧金山举行。据披露，本届JPM的议题与参会企业或将高度集中于六大核心领域，其中生物技术板块占比最高，预计接近35%。目前，已有多家国内企业确认参会，且覆盖CXO与创新药两大核心群体。从行业趋势看，本届JPM或将进一步强化两条技术主线。进入2026年，这一趋势仍在延续。宜联生物B7H3 ADC授权给罗氏此次JPM 2026将成为国内药企集中展示核心分子竞争力、推动海外BD合作的重要窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03696","LU2328871848.SGD","09688","BK1161","09995","02359","02269","BK1583","06978","LU1969619763.USD","02615","06160","01276","01530"],"gpt_icon":0},{"id":"2602902425","title":"中国力量在JPM大会的闪耀时刻：24家国产企业双线发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2602902425","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602902425?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:36","pubTimestamp":1768206992,"startTime":"0","endTime":"0","summary":"而今年，中国力量成为舞台上最耀眼的星光之一：24家国产医药企业集体亮相，以“主会场引领、亚太专场扩容”的双线布局，向世界展示中国医药产业的创新硬实力与全球化野心。结 语从主会场的核心发声到亚太专场的集体亮相，24家中国药企在JPM大会的舞台上，用实打实的研发成果、商业化突破与海外合作，书写着中国医药的全球化篇章。这不仅是中国力量的闪耀时刻，更预示着2026年中国创新药将在全球舞台上迎来更多突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1770034418.SGD","01276","LU1251922891.USD","LU0588546209.SGD","LU1719994722.HKD","LU2328871848.SGD","BK1574","LU0307460666.USD","06978","06990","BK1500","BK1588","06160","02269","09688","LU1303224171.USD","LU1969619763.USD","LU2488822045.USD","01530","BK1583","BK1161","09995","02359"],"gpt_icon":0},{"id":"2602518938","title":"每日卖空追踪 | 荣昌生物 01月12日卖空量成交9.2万股，卖空比例为2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602518938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602518938?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206641,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间01月12日，跌1.95%，卖空量成交9.2万股，较上一交易日减少73.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165311a4b9d87a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165311a4b9d87a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","LU2328871848.SGD","BK1161","BK1574","09995"],"gpt_icon":0},{"id":"2602659414","title":"【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2602659414","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602659414?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:45","pubTimestamp":1768203955,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际研报指出，上周恒生医疗保健指数上涨10.3%，跑赢恒生指数10.7个百分点。2026年年初以来，恒生医疗保健指数涨幅为12.4%，跑赢恒生指数10.0个百分点。该机构指出，上周部分细分板块龙头显著反弹，主要归因于：一方面，前期获利了结资金影响逐步出清；另一方面，市场对2026年创新药产业链情绪偏积极，看好管线优质和推进速度快、有BD潜力、股价位置合理的板块龙头，如荣昌生物、映恩生物等。同时，受到AI主题热度高涨影响，AI医疗概念走强，高增速、业绩兑现度高的主题标的医脉通、平安好医生涨幅明显。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1615","BK0239","06978","LU1969619763.USD","LU1064131003.USD","LU1046422090.SGD","BK1587","LU1235295612.USD","BK1571","BK1617","BK1583","09995","LU2543165471.USD","HK0000252160.HKD","01833","LU2148510915.USD","09606","159992","02192","BK1142","LU2488822045.USD","BK1515","LU0049112450.USD","BK1189","LU1064130708.USD","BK1161","HK0000252152.HKD","BK1219","HK0000500386.USD","LU2328871848.SGD","BK1247","688331"],"gpt_icon":0},{"id":"2602559242","title":"医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559242","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602559242?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:24","pubTimestamp":1768137841,"startTime":"0","endTime":"0","summary":"海内外共振，加速抢占全球科技高地：脑机接口技术当前已经成为全球各国科技竞争的战略高地之一。当前全球脑机接口真处于爆发前夜，我国脑机接口产业有望迎来黄金发展期，建议关注微创脑科学、翔宇医疗、美好医疗等。从自免角度，建议关注康诺亚、益方生物、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228","01276","02172","BK1100","BK1515","BK1617","BK1574","BK1161","03933","02615","09995","09939","BK1141","09926"],"gpt_icon":0},{"id":"2602753679","title":"每周股票复盘：荣昌生物（688331）拟回购股份金额不低于2000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602753679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602753679?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:14","pubTimestamp":1768076051,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，荣昌生物报收于96.96元，较上周的77.79元上涨24.64%。本周，荣昌生物1月9日盘中最高价报98.0元。荣昌生物当前最新总市值546.57亿元，在生物制品板块市值排名2/51，在两市A股市值排名365/5182。本周关注点公司公告汇总：荣昌生物拟使用自有资金回购股份，金额不低于2000万元且不超过4000万元。截至2025年12月31日，公司尚未开始回购股份，后续将根据市场情况择机实施回购，并按规定履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","BK1574","LU1969619763.USD","09995","BK1583","LU1064131003.USD","LU2148510915.USD","LU2328871848.SGD","BK0239","LU1064130708.USD","688331","BK1161"],"gpt_icon":0},{"id":"1168058667","title":"一周港股牛熊榜 | 开年医药股狂欢，劲方医药周涨45%；晶泰控股、英矽智能周升25%；融创中国、鸿腾精密下挫11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168058667","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168058667?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:22","pubTimestamp":1767950551,"startTime":"0","endTime":"0","summary":"总结全周， $恒生指数$ 跌106点或0.41%， $恒生科技指数$ 跌49点或0.86%；本周市值百亿以上、日均成交千万以上表现最好五只股票是 $劲方医药-B$ 、 $量化派$ 、 $荣昌生物$  、$晶泰控股$  、$英矽智能$ ；表现最差的五只股票是 $云知声$ 、 $融创中国$、  $鸿腾精密$  、$汇聚科技$  、$环球新材国际$ 。重点关注创新药产业链，景气度预计将持续向上。新年第一个完整周，英矽智能升25.07%。本公司亦已取得联交所批准换股股份上市及买卖。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01729","02685","03696","01918","02228","02595","06616","09678","09995","06088"],"gpt_icon":1},{"id":"2602883875","title":"荣昌生物01月09日获主力加仓1250.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602883875","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602883875?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946540,"startTime":"0","endTime":"0","summary":"01月09日, 荣昌生物股价涨2.82%，报收94.65元，成交金额3.9亿元，换手率1.99%，振幅6.14%，量比0.90。荣昌生物今日主力资金净流入1250.4万元，连续5日净流入，上一交易日主力净流入1114.1万元。该股近5个交易日上涨28.45%，主力资金累计净流入1.1亿元；近20日主力资金累计净流入3846.6万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162014a4af6f1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162014a4af6f1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","09995"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU1934453819.USD","LU0307460666.USD","LU0501845795.SGD","LU1152091168.USD","LU0417516571.SGD","01093","LU0039217434.USD","BK1589","LU0561508036.HKD","01877","IE0008369823.USD","LU0516422440.USD","LU1807302812.USD","09926","LU2476274720.SGD","LU0043850808.USD","BK0012","LU2148510915.USD","02142","LU1064131003.USD","LU2097828474.EUR","LU1960683339.HKD","01801","09995","IE00B5MMRT66.SGD","LU3063872942.SGD","06978","LU1979443071.USD","02616","06160","LU1993786604.SGD","BK0183","BK1500","LU0588546209.SGD","159992","LU1242518857.USD","LU2097828805.USD","LU0067412154.USD","01177","06185","09688","LU1226287792.SGD","02269","LU1328277881.USD","LU0516422952.EUR","LU0502904849.HKD","601688","BK1141","LU0315179316.USD"],"gpt_icon":0},{"id":"2601910360","title":"每日卖空追踪 | 荣昌生物 01月08日卖空量成交39.35万股，卖空比例为10.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601910360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601910360?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861044,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间01月08日，涨0.38%，卖空量成交39.35万股，较上一交易日减少66.34%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108165204a4ab49d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108165204a4ab49d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","LU2328871848.SGD","LU1969619763.USD","09995","BK1161"],"gpt_icon":0},{"id":"2601945360","title":"荣昌生物01月08日获主力加仓1114.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601945360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601945360?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:15","pubTimestamp":1767860135,"startTime":"0","endTime":"0","summary":"01月08日, 荣昌生物股价涨0.38%，报收92.05元，成交金额3.6亿元，换手率1.84%，振幅5.51%，量比0.82。荣昌生物今日主力资金净流入1114.1万元，连续4日净流入，上一交易日主力净流入6289.7万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为85.71%，平均涨幅为8.02%。该股近5个交易日上涨26.88%，主力资金累计净流入9905.5万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1249.7万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162049a4ab2a8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108162049a4ab2a8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU2328871848.SGD","BK1161","09995","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2601351333","title":"交易总额突破1300亿美元！2025年全球创新药BD交易全景分析及趋势预判","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351333","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351333?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:55","pubTimestamp":1767837325,"startTime":"0","endTime":"0","summary":"本文将基于药渡咨询的深度调研数据，对2025年全球及中国创新药BD交易的全景进行深度剖析，并对未来五年的发展趋势进行前瞻性预判。全景回顾：全球与中国BD交易的双向奔赴1.交易规模：中国领跑全球增长2025年，全球生物医药BD授权交易呈现出显著的回暖与扩张态势。此次交易总金额高达42.3亿美元，直接推动荣昌生物股价在两周内涨幅超105%。结 语2025年标志着中国创新药BD交易从“量变”走向“质变”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09926","02615","09995","06978"],"gpt_icon":0},{"id":"1159794048","title":"荣昌生物(09995)发布2025年12月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1159794048","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159794048?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:41","pubTimestamp":1767778912,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年1月7日更新发布截至2025年12月31日的股份变动月报表。报告期内，公司注册资本与已发行股份总数均维持不变。已发行H股为208,581,239股，已发行A股为355,129,004股，均无新增发行或回购注销。\\n\\n截至本月末，公司无购回或注销活动，股本总数维持稳定。公司同时确认，已遵守香港联合交易所有限公司上市规则及其他适用法律法规。公告由公司董事王威东签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1673},{"period":"1month","weight":0.1747},{"period":"3month","weight":0.0369},{"period":"6month","weight":0.3528},{"period":"1year","weight":6.9046},{"period":"ytd","weight":0.2889}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0243},{"period":"3month","weight":0.0459},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.3957},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.090264},{"month":2,"riseRate":0.8,"avgChangeRate":0.209338},{"month":3,"riseRate":0.4,"avgChangeRate":-0.022811},{"month":4,"riseRate":0.8,"avgChangeRate":0.104301},{"month":5,"riseRate":0.4,"avgChangeRate":-0.023394},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}